PXS.F Paragon Care Limited
- Market cap
- EUR 146M
- P/E
- -
- P/B
- 0.81x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PXS.F undervalued?
Graham numberThe Graham number of Paragon Care Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paragon Care Limited fundamental analysis
No fundamental analysis for Paragon Care Limited yet.
Paragon Care Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company distributes capital equipment, medical consumables, and online procurement solutions for hospitals, as well as offers pharmacy products, dispensary supplies, private label solutions, and digital ordering platforms to pharmacies, pharmacy groups, and hospital pharmacy services; medical consumables, nutrition supplies, aged care equipment, resid…
Full company profileParagon Care Limited financial statements
Paragon Care Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 93.3M | 117M | 137M | 236M | 232M | 236M | 248M | 308M | 2.97B | 3.68B |
| Gross Profit | 36.4M | 46.0M | 54.7M | 95.1M | 86.8M | 90.3M | 103M | 126M | 177M | 347M |
| Operating Income | 11.3M | 15.6M | 11.0M | 16.4M | 2.07M | 17.5M | 18.7M | 24.1M | 28.4M | 6.42M |
| EBITDA | - | 16.0M | 15.9M | 28.2M | -63.5M | 25.7M | 24.4M | 37.1M | 44.8M | 46.2M |
| Net Income | 7.53M | 10.2M | 11.0M | -14.4M | -77.3M | 8.28M | 7.14M | 10.8M | 8.38M | -16.0M |
| EPS | - | 0.06 | 0.04 | -0.04 | -0.23 | 0.02 | 0.02 | 0.02 | 0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 148M | 166M | 350M | 384M | 292M | 292M | 437M | 449M | 1.13B | 1.37B |
| Total Liabilities | 75.0M | 83.4M | 180M | 192M | 180M | 170M | 195M | 197M | 839M | 1.08B |
| Shareholders' Equity | 72.8M | 82.7M | 170M | 192M | 112M | 122M | 236M | 243M | 292M | 296M |
| Cash & Short-term Investments | 19.1M | 18.6M | 40.4M | 34.2M | 24.5M | 33.2M | 46.2M | 22.6M | 19.9M | 23.7M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.76M | 12.0M | 7.56M | 1.16M | 5.29M | 27.5M | 19.0M | 17.7M | - | - |
| Capital Expenditure | 2.22M | 1.05M | 2.76M | 5.83M | 2.32M | 3.33M | 3.12M | 20.8M | 19.3M | 33.2M |
| Free Cash Flow | - | 7.41M | 1.01M | -8.56M | -1.98M | 22.2M | 14.4M | -3.30M | 33.1M | -4.06M |
| Ratios | ||||||||||
| ROE | 10.3% | 12.3% | 6.4% | -7.5% | -68.8% | 6.8% | 3.0% | 4.4% | 2.9% | -5.4% |
| ROA | 5.1% | 6.1% | 3.1% | -3.7% | -26.4% | 2.8% | 1.6% | 2.4% | 0.7% | -1.2% |
| Net Profit Margin | 8.1% | 8.7% | 8.0% | -6.1% | -33.4% | 3.5% | 2.9% | 3.5% | 0.3% | -0.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Paragon Care Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 18, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | AUD 12.6M | 0.01 | 150.5% |
| 2023 | AUD 7.89M | 0.01 | 73.3% |
| 2022 | EUR 7.89M | 0.02 | 110.4% |
| 2021 | EUR 7.89M | 0.02 | 95.3% |
| 2020 | EUR 7.89M | 0.02 | - |
| 2019 | EUR 8.70M | 0.03 | - |
| 2018 | EUR 4.70M | 0.02 | 42.9% |
| 2017 | EUR 3.52M | 0.02 | 34.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jul 19, 2011.
Who owns Paragon Care Limited
- Insiders 69.47%
- Institutions 7.99%
- Public & others 22.53%
- Shares outstanding 1.66B
- Free float 520M
Paragon Care Limited company profile
- Company name
- Paragon Care Limited
- Ticker
- PXS.F
- ISIN
- AU000000PGC4
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- June
- Address
- 77-97 Ricketts Road, Mount Waverley, VIC, Australia, 3149
- Phone
- 61 3 8833 7800
- Website
- paragoncare.com.au
About Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company distributes capital equipment, medical consumables, and online procurement solutions for hospitals, as well as offers pharmacy products, dispensary supplies, private label solutions, and digital ordering platforms to pharmacies, pharmacy groups, and hospital pharmacy services; medical consumables, nutrition supplies, aged care equipment, resident safety technology, and digital procurement solutions; and orthopedic implants, surgical technologies, and patient-focused solutions for orthopedic surgeons, hospitals, and healthcare providers. It also offers ophthalmic and optometry equipment, including diagnostic devices, OCT systems, slit lamps, dry eye treatment solutions, surgical instruments, and vision testing tools for eye care professionals and day surgery facilities; treatment room consumables, vaccines, diagnostic equipment, and infection prevention products for general practices, medical centres, and community healthcare providers; dental consumables, infection control supplies, dental equipment, imaging and technical support; laboratory equipment, scientific consumables, diagnostic instruments, and technical support; and diagnostic technologies, laboratory systems, and technical expertise. In addition, the company offers medical devices and clinical consumables; digital x-ray, ultrasound, molecular imaging, mobile c-arm, imaging navigation systems, and AI-driven software solutions; vitamins, supplements, herbal, and naturopathic products; veterinary consumables, pharmaceuticals, diagnostic equipment, and specialist clinical products; aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; and surgical robotics and robotic-assisted surgical systems hospitals and healthcare facilities. The company is based in Mount Waverley, Australia.
Paragon Care Limited management
4- Ms. Carmen Rose RileyCEO, MD & Executive Director
- Mr. David Keith CollinsCFO, Executive Director of M&A and Director
- Mr. James KhoshabaChief Information Officer
- Mr. Michael Sapountzis AGIA, B.Com., L.L.B., M.A.I.C.D.Company Secretary